Popular Articles

Discovery Of Genetic Links To Age Of First Menstrual Period And Menopause
Newly identified gene variants associated with the age at which females experience their first menstrual period and the onset of menopause may help shed light on the prevention of breast and endometrial cancer, osteoporosis, and cardiovascular disease.
generic viagra online
Awarepoint Announces Real-Time Location System (RTLS) Deployment To Moores Cancer Center
Awarepoint Corporation announced deployment of its Real-time Location System (RTLS) at the Rebecca and John Moores UCSD Cancer Center. This deployment adds a third UCSD Medical Center hospital to Awarepoint"s RTLS coverage, which currently includes the system"s Thornton and Hillcrest campuses. The Awarepoint enterprise RTLS installation has now been expanded to include nearly 1.5 million square feet with more than 2,000 assets under management, covering three hospitals across nearly 14 miles.
News of the day
Prevention Program Helps Teens Override A Gene Linked To Risky Behavior
A family-based prevention program designed to help adolescents avoid substance use and other risky behavior proved especially effective for a group of young teens with a genetic risk factor contributing toward such behavior, according to a new study by researchers at the University of Georgia. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA), components of the National Institutes of Health, supported the study, which appears in the May/June issue of Child Development.
Endocrinology

Life Sciences Blueprint To Build A Strong And Healthy Future For Britain

A new Blueprint to put innovation at the heart of healthcare delivery was launched by Lord Drayson and Lord Darzi at Imperial College London. The Office for Life Sciences (OLS) Blueprint sets out to transform the UK environment for life sciences companies and ensure faster patient access to cutting-edge medicines and technologies. The OLS forms part of the Government"s active industrial policy. Agreed across Government, and with industry, academia and the NHS, key actions include: -- The Government, with the National Institute for Health and Clinical Excellence (NICE), will introduce an "Innovation Pass", a 3-year initiative that will make selected innovative medicines available on the NHS for a time-limited period. The Pass will be piloted in 2010/2011, with a budget of ÷£25 million; (cf 2.5) -- The NHS Chief Executive will review system levers and incentives, including Payment by Results, to accelerate the uptake of medical technologies; (cf 2.9) -- The Government will reinforce the need for greater emphasis on research and clinical trials in the next NHS Operating Framework; (cf 2.10) -- From 2010, the Society of Biology will begin to accredit undergraduate bioscience degrees to help ensure that graduates leave with the core mathematical and practical skills and competencies required by employers; (cf 3.5) -- The Government will support the formation of a UK Life Sciences Super Cluster to co-ordinate work across industry, Higher Education and the NHS, and to boost international recognition of UK life sciences; (cf 3.9) -- The Technology Strategy Board will launch an ÷£18 million "RegenMed" programme of investment to support commercial R&D with additional funding from the Medical Research Council, the Engineering and Physical Sciences Research Council, and the Biotechnology and Biological Sciences Research Council. The TSB has also committed to improve its expertise in the life sciences. (cf 4.8) -- The Government will invest an extra ÷£1 million to promote the UK and NHS brands at flagship life sciences events in the UK and overseas. Lord Drayson, Minister for Science & Innovation, said: "The UK life sciences have everything going for them: world-class facilities, talented scientists and entrepreneurial flair. By championing innovation, the NHS can support the life sciences industry in developing ways to improve people"s health. And we are changing how industry, academia, Government and the NHS work together to create jobs and ensure a bright future for this country." Lord Darzi, Health Minister for Quality and Innovation, said: "By placing innovation at the heart of healthcare delivery we will help create a pioneering NHS, one that responds to patients expectations, and one where the adoption of new ideas and the diffusion of innovation is encouraged and supported. "Establishing a culture of innovation is also essential for the NHS to meet any current economic challenges, and the Life Sciences Blueprint will help us continue to support this country"s knowledge industries and ensure that we benefit from the competitive edge which they provide." Andrew Dillon, Chief Executive of NICE, said: "Securing a successful future for the life sciences industries is important for patients and the UK economy. NICE is committed to engaging constructively with companies and we are extending the access that companies have to us, as we appraise their products. The Innovation Pass is an opportunity for data to be gathered on potentially important new treatments. NICE has been involved in discussions about the Innovation Pass, and we are looking forward to continuing to play a key role in developing the Pass." The Blueprint forms a key part of Building Britain"s Future, the Government"s vision for the country"s future on the other side of the recession. As first set out in "New Industries, New Jobs", the Government is pursuing a new, more active industrial policy to drive growth and create high-value jobs of the future. Department of Health, UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):